The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
about
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cellsEmerging preclinical pharmacological targets for Parkinson's diseaseGPR109A and vascular inflammationNicotinic acid receptor agonists differentially activate downstream effectorsNiacin stimulates adiponectin secretion through the GPR109A receptorNaturally occurring HCA1 missense mutations result in loss of function: potential impact on lipid deposition.The hypophagic response to heat stress is not mediated by GPR109A or peripheral β-OH butyrateSelective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation.Future of GPR109A agonists in the treatment of dyslipidaemia.Upregulation of GPR109A in Parkinson's diseaseNicotinic acid modulates intracellular calcium concentration and disassembles the cytoskeleton.Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.Effects of niacin on atherosclerosis and vascular function.High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.Retinal transfer of nicotinate by H+ -monocarboxylate transporter at the inner blood-retinal barrier.Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signalingInvolvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic MiceOrphan GPCR research.Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium.Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.Novel patent publications on high-affinity nicotinic acid receptor agonists.Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A: WO2008051403.The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization.Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradationBHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activationDiagnosis and treatment of severe hypertriglyceridemia.Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.Constitutive expression of HCA(2) in human retina and primary human retinal pigment epithelial cells.Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease.Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.
P2860
Q24297428-EF6C6F1A-705A-4414-BE59-5E621CF427E5Q24316354-AF9A56E8-174B-4F50-BBB7-77910DED2D37Q26764724-79668368-0DAD-4CB0-B802-EE762AE1F870Q28287747-FFF46FE7-12A8-4863-AC51-B8DDBEFC3960Q28298974-11B74B93-B5A8-41F9-A589-E179ECBC8609Q28575089-E85EEAB5-78EE-45FD-AB8A-4C4819509385Q30414585-5F35788C-1DC3-4C24-B32E-783AE059AC36Q31051889-2941D690-2302-45CD-A432-6E028DF23FFDQ33789758-54C03741-76E5-4C46-8235-14A7336484F1Q33927010-B9D6EB56-7948-4BF6-834F-1EF94BCBBE7EQ34171831-C7EE0B8A-84FD-465D-9C15-0A1C03EA3949Q34361793-FCDBAC9B-2727-4FA8-B62D-6B7C079398F4Q34487985-B88B8FFC-94EF-40FD-895B-10EFE02AC33CQ34565228-4E2007FB-8D7B-4E3A-B9FE-4EA7C1C0A4B3Q34624990-21907636-5A18-40E7-B4C1-4D5DBFD1FAA5Q34712851-6BF2C095-E058-4308-BFF3-78267FF2043AQ35025103-7B5EE6AC-5AE8-4F30-91F4-E1DB7E960A82Q35132366-BC4E1E1F-C3EB-45CE-B9BB-871778513F22Q35575144-72F77D4E-9746-42DD-9E82-9B8E674BD6D4Q35575652-62DD1B87-0FC1-4AFE-AB49-D59B992F638DQ35608570-FDC8C8B5-008F-4E48-9904-371885D8C767Q35660100-C455D053-ACBF-42A8-9E65-F058FE0A86A4Q36102106-B68D178E-BEF6-409A-8382-676C2599997CQ37028758-08C9EBC2-887D-48E8-9D4D-560E333601D3Q37097541-88D293FB-4A72-4766-98A9-FFE5E792468BQ37230403-0BAE3702-4532-41CE-9EEC-3D9D8EF424AFQ37376937-D64389EE-DFE8-4432-913F-FC80B67C6012Q37529810-3709EC2E-E5A5-4A70-ADBB-AB099F857095Q37536057-4C8021D2-F6FB-4CC6-8A8F-27DD60711DB1Q37621301-66E90BD8-54AE-4CC6-975B-FE2DCC8C9C07Q37635019-B152CF7B-4822-4F3E-A171-85087115597DQ37667487-CB08D995-9CB6-4516-97CB-6A876A31588AQ37679063-73159D83-43EC-4C70-920A-B1328A241100Q37720336-38C05C71-252D-406E-945B-D7AE9A724807Q37998115-DD05FD58-CF10-4365-851B-0960822E6748Q38351961-604B8DDA-32BE-4D84-A0D6-6902ADFE0EC1Q38948892-321AD717-2976-4B2F-BEDE-7D27936D3A55Q39064720-1FFF21E5-4968-4606-804B-8EFFB6BE501BQ39132612-346728D5-DD84-49AA-93AE-D16389A0C35DQ39303280-2F1FDE4A-E5EC-4EB3-BFA7-894AE95A7DDF
P2860
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@ast
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@en
type
label
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@ast
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@en
prefLabel
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@ast
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@en
P1476
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
@en
P304
P356
10.1016/J.TIPS.2006.05.008
P577
2006-07-01T00:00:00Z